Eli Lilly Slashes Prices on Weight-Loss Drug to Boost Demand

Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease investor concerns over sales performance and address competition from compounded versions of the drug.

Eli Lilly has announced a significant price reduction for its popular weight-loss drug, Zepbound, in the United States by offering higher doses in vials. This new pricing undercuts the cost of the injector pen versions by $150, marking a strategic move to increase demand amid competitive market pressures.

For $499 a month, patients can now purchase 7.5mg and 10mg vials through Lilly's direct channel, nearly 23% cheaper than the auto-injectors. This price realignment comes in response to uncompensated patients seeking cost-effective alternatives, as well as an attempt to outmaneuver Danish rival Novo Nordisk, which sells Wegovy without vial options.

This pricing strategy follows the FDA's removal of Zepbound and Wegovy from its shortage list, prompting ensuing legal actions from compounding pharmacies. Telehealth providers, such as Hims & Hers Health, have also expressed concerns over reduced capacities to sell compounded variants of the drug. Lilly requires patients to refill their prescriptions within 45 days to ensure adherence to FDA-approved dosing standards.